.jpeg)
{{ variable.name }}
Common name: Dutasteride
Trade name: Avoda
All names: Dutasteride, Dutasteride, Avodart, Dutasteride, Avodart, Duagen
Indications:
This product is mainly used for the treatment of patients with prostatic hyperplasia (BPH). It can improve the symptoms of BPH for a long time. This product can also reduce the incidence of prostate cancer.
Usage and dosage:
Orally, 5 mg each time, once a day.
The tablet should be swallowed whole and should not be chewed or opened as the contents may irritate the oropharyngeal mucosa. Capsules can be taken with or without food.
Adverse reactions:
The most common adverse reactions are gynecomastia (including breast enlargement, breast tenderness), impotence, ejaculation disorder and decreased sexual desire.
Patients with heart disease should use with caution.
This product is mainly metabolized by the liver, and should be used with caution in patients with liver function impairment.
Contraindications:
It is contraindicated in patients with a history of allergy to this product and other 5α-reductase inhibitors.
It is contraindicated in patients with undetermined BPH (possible canceration).
The reproductive toxicity of this product is X, and it is prohibited for pregnant women.
Note:
Don’t donate blood within 6 months of stopping using this product.
This product has no specific antidote, and supportive care should be taken after drug overdose.
When patients taking this product use serum prostate-specific antigen (PSA) indicators to detect prostate cancer, doctors should be reminded to fully consider the important factors that lead to a decrease in serum PSA values due to the patient's taking this product.
Storage:
Stored in a cool and dry place.
Mechanism of action:
Testosterone is converted into dihydrotestosterone under the action of 5α-reductase. Dihydrotestosterone can promote the growth and development of the prostate. There are two subtypes of 5α-reductase, namely type I isoenzyme and type II isoenzyme. Type I isoenzyme has reproductive activity, and type II isoenzyme is involved in the conversion of testosterone in the skin and liver. This product is a relatively specific 5α-reductase inhibitor. It inhibits type I and type II 5α-reductase isoenzymes by forming an enzyme complex, inhibits the conversion of testosterone into dihydrotestosterone (DHT), and then inhibits the production of the male hormone dihydrotestosterone, thereby inhibiting the growth of the prostate in patients with benign prostatic hyperplasia (BPH). 0.5 mg per day, the DHT-lowering effect of this product reaches its peak after 1 to 2 weeks of medication, and plasma DHT can be reduced by 85% to 90%. Patients with prostate enlargement took 5mg of medication every day, and their DHT was significantly reduced in 12 weeks.